53rd at Third 885 Third Avenue New York, New York 10022-4834 Tel: +1.212.906.1200 Fax: +1.212.751.4864 www.lw.com | ||
FIRM / AFFILIATE OFFICES | ||
Beijing | Moscow | |
Boston | Munich | |
Brussels | New York | |
Century City | Orange County | |
Chicago | Paris | |
Dubai | Riyadh | |
Düsseldorf | San Diego | |
Frankfurt | San Francisco | |
Hamburg | Seoul | |
Hong Kong | Shanghai | |
Houston | Silicon Valley | |
London | Singapore | |
Los Angeles | Tokyo | |
Madrid | Washington, D.C. | |
Milan |
April 12, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Tonya K. Aldave
Justin Dobbie
Re: | MediWound Ltd. Registration Statement on Form F-3 Filed on March 25, 2019 File No. 333-230490 |
CIK No. 0001593984
Ladies and Gentlemen:
We are in receipt of the Staff’s letter dated April 8, 2019 with respect to the above-referenced Registration Statement on Form F-3 (the “Registration Statement”). We are responding to the Staff’s comment on behalf of MediWound Ltd. (the “Company”) as set forth below.
For ease of reference, we have set forth the Staff’s comment and the Company’s response below. Defined terms used but not otherwise defined herein have the meanings ascribed to such terms in the Registration Statement.
General
1. | Please provide us with support for your conclusion that you are eligible to conduct a primary offering under General Instruction I.B.1 of Form F-3. In this regard, provide us with your calculation of the aggregate market value of the shares held by non-affiliates. |
Response:
The Company respectfully advises the Staff that at the date of the filing of the Registration Statement on March 25, 2019, the Company determined that its unaffiliated market capitalization was $75 million or more consistent with the requirements of General Instruction I.B.1 of Form F-3 and the related instruction thereto. The key parameters for the calculation were as follows:
Closing share price on March 20, 2019 (date within 60 days of the filing date) | $5.24 |
Total outstanding shares on March 20, 2019 | 27,178,839 shares |
Outstanding shares held by affiliates as of March 20, 2019: | |
Clal Biotechnology Industries Ltd. | 9,429,555 shares |
Gal Cohen | 131,102 shares |
Lior Rosenberg | 1,850,572 shares |
Other directors and officers | |
(each less than 1% holders per Form 20-F) | 0 shares |
Total outstanding shares on March 20, 2019 held by non-affiliates | 15,767,610 shares |
Total unaffiliated market capitalization on March 20, 2019 | $82.2 million |
By way of further explanation, the Company notes that the following shareholders, Wellington Management Group LLP, Migdal Insurance & Financial Holdings Ltd. and Yelin Lapidot, are not its affiliates. The Company confirms that they are not represented on its board and do not otherwise exercise control over, or are under common control with, the Company.
* * *
We hope the foregoing has been responsive to the Staff’s comment and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact us at (212) 906-2916 with any questions or further comments you have regarding this filing or if you wish to discuss the above. Thank you in advance for your cooperation in connection with this matter.
Very truly yours, /s/ Nathan Ajiashvili Nathan Ajiashvili of LATHAM & WATKINS LLP |
cc: (via email)
Gal Cohen, MediWound Ltd.
Yaron Meyer, MediWound Ltd.
Josh Kiernan, Latham & Watkins LLP